BioCentury | Nov 26, 2020
Product Development

U.S. government spending on Abbott BinaxNOW outstrips other rapid COVID-19 tests: Data Byte

Abbott’s BinaxNOW test has replaced its predecessor as the Trump Administration’s favorite COVID-19 test. A fact sheet released by HHS Tuesday showed the U.S. federal government has spent $760 million on the antigen test from Abbott...
BioCentury | Nov 14, 2020
Product Development

Denali holds gains after first human proof of concept for brain delivery tech

Denali this week reported the first clinical proof-of-concept data from its transport vehicle (TV) technology, which shuttles large molecules across the blood-brain barrier, pushing its shares to...
BioCentury | Nov 2, 2020
Deals

Realignment around acquired NK assets primed Kiadis for €308M Sanofi buyout

A modestly-priced acquisition of an NK cell platform company in spring 2019 set up Kiadis for a premium takeout by its partner Sanofi, even after the Dutch biotech discontinued its lead T cell program late...
BioCentury | Oct 21, 2020
Product Development

UCSF’s virus-host protein interaction maps ID targets for COVID-19, future coronaviruses

A UCSF-led team has identified host pathways that could inform development of countermeasures against future coronaviruses, as they interact with multiple coronaviruses that recently made the leap...
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

AI and machine learning company insitro appointed Roger Perlmutter, EVP and president of Merck Research Laboratories, as its first independent board member.  Kiran Mazumdar-Shaw has joined the board of PureTech Health plc (LSE:PRTC). Mazumdar-Shaw is the co-founder...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

FDA moving quickly on Biogen’s aducanumab Biogen Inc. (NASDAQ:BIIB) added $1.4 billion in market cap Monday, as its shares rose $8.73 (3.2%) to $282.04, after FDA said it will hold an advisory...
BioCentury | Sep 18, 2020
Product Development

Harmonizing limits of detection for FDA-authorized COVID-19 diagnostics

Comparing the limits of detection for COVID-19 molecular diagnostic tests offers a window into their relative sensitivity and potential to produce false negative results. New data published by FDA, based...
BioCentury | Sep 11, 2020
Product Development

Loxo’s Bilenker on why reimbursement crisis is creating innovation, access crises: a BioCentury audio interview

COVID-19 has spotlighted the critical role of diagnostics and focused the world’s attention on the threats posed by infectious pathogens. Awareness is good, but what’s really needed to advance diagnostics...
BioCentury | Sep 9, 2020
Product Development

McMurry-Heath: COVID-19 raises stakes for industry to take the lead on promoting science: a BioCentury audio interview

Michelle McMurry-Heath, three months into her role as president and CEO of BIO, sees the pandemic as a crucial time for the biopharma industry to tell its story better to the public, and ensure its...
BioCentury | Sep 9, 2020
Product Development

Roche’s Anderson wants industry to keep its foot on the gas for infectious disease, post-pandemic: a BioCentury audio interview

There will be no turning back to business as usual for drug developers and regulators after COVID-19, according to Bill Anderson, CEO of Roche Pharmaceuticals. But while he’s optimistic about speeding up timelines and changing...
Items per page:
1 - 10 of 746